02:17 PM EDT, 06/23/2025 (MT Newswires) -- Health care stocks were mixed Monday afternoon with the NYSE Health Care Index easing 0.3% and the Health Care Select Sector SPDR Fund (XLV) up 0.1%.

The iShares Biotechnology ETF (IBB) dropped 0.2%.

In corporate news, Novo Nordisk ( NVO ) ended its collaboration with Hims & Hers Health ( HIMS ) on the sale of weight loss drug Wegovy over concerns about "illegal mass compounding and deceptive marketing." Hims & Hers shares dropped 32%, and Novo slid 5.7%.

Revolution Medicines ( RVMD ) shares rose 2% after the company won Breakthrough Therapy Designation for its drug candidate daraxonrasib from the US Food and Drug Administration.

Sana Biotechnology ( SANA ) reported positive six-month results from a first-in-human study evaluating UP421, an allogeneic islet cell therapy for type 1 diabetes. The stock was little changed, erasing earlier gains.

Exelixis ( EXEL ) shares rose 8.3% after the company said its phase 3 trial showed a "statistically significant" overall survival benefit in the combination of zanzalintinib and atezolizumab in patients with a type of metastatic colorectal cancer.